Education
About Us
Working with TipRanks
Follow Us
Telix Pharmaceuticals Ltd. (AU:TLX)
OTHER OTC:TLX
TLX Stock Chart & Stats
AU$10.55
-AU$0.59(-2.38%)
At close: 4:00 PM EST
AU$10.55
-AU$0.59(-2.38%)
Day’s Range― - ―
52-Week RangeAU$10.47 - AU$31.97
Previous CloseN/A
Volume456.62K
Average Volume (3M)2.17M
Market Cap
AU$3.57B
Enterprise ValueAU$3.79B
Total Cash (Recent Filing)AU$207.16M
Total Debt (Recent Filing)AU$418.25M
Price to Earnings (P/E)211.8
Beta1.42
Next Earnings
Aug 20, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding338,777,040
10 Day Avg. Volume3,366,578
30 Day Avg. Volume2,166,331
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)14.35
Price to Sales (P/S)10.41
P/FCF Ratio906.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$25.89Price Target Upside145.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.09
Revenue Forecast (FY)AU$1.34B
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressBiPASS phase three dosing underway with rapid recruitment in Australia and inclusion of North American patients could strengthen the data package and broaden the imaging agent's approved indication, increasing potential scan volume.
Regulatory PathwayAnticipated resubmission of the brain imaging agent Pixclara to the FDA could enable US approval and add a major product to the company's commercial lineup, supporting revenue expansion.
Revenue MomentumPre‑reported higher total revenue driven by increased diagnostic sales indicates improving commercial traction that could bolster investor confidence and future financial forecasts.
Bears Say
Elevated Execution RiskAnalyst classification of the investment as high risk highlights heightened uncertainty around clinical, regulatory and commercial execution that may increase share price volatility.
Regulatory And Legal DependenciesFuture upside relies on regulatory approval, guideline placement, resolution of safety data questions and an ongoing SEC probe, any of which could cause setbacks or pricing pressure if outcomes are unfavorable.
Valuation PressureMultiple reductions in price targets signal tempered expectations for the stock's valuation, which could constrain upside and dampen market sentiment.
Telix Pharmaceuticals News
TLX FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest share price was AU$10.47 and its highest was AU$31.97 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is AU$3.57B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 200 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Jan 20, 2026. The company reported AU$0.057 earnings per share for the quarter, beating the consensus estimate of AU$0.039 by AU$0.019.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.07.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 338,777,040 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of AU$0.057 in its last earnings report, beating expectations of AU$0.039. Following the earnings report the stock price went up 1.862%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:TLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Telix Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$25.89 (145.38% Upside)
AU$25.89 (145.38% Upside)
Blogger Sentiment
Bullish
AU:TLX Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.43%
12-Months-Change
Fundamentals
Return on Equity
3.21%
Trailing 12-Months
Asset Growth
138.86%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
TLX Stock 12 Month Forecast
Average Price Target
AU$25.89
▲(145.38% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Mesoblast Limited
―
Neuren Pharmaceuticals Limited
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Options Prices
Currently, No data available
---